Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LT3001 Drug Product · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LT3001 Drug Product | EXPERIMENTAL | Administered by intravenous infusion |
| Placebo | PLACEBO_COMPARATOR | Administered by intravenous infusion |
| Name | Type | Description |
|---|---|---|
| LT3001 Drug Product | DRUG | LT3001 Drug Product administered once by intravenous infusion |
| Placebo | DRUG | Placebo administered once by intravenous infusion |
Inclusion Criteria: 1. Subject or subject's legal representative consents to participation by signing the informed consent form (ICF) after receiving full information about the study. 2. Subject is aged 18 to 90 years, inclusive, at the time of Screening (Visit 1). 3. Subject has an NIHSS ≥6. 4. Su...
LT3001 Drug Product is an investigational small molecule being developed for the treatment of acute ischemic stroke. It is currently in Phase 2 clinical development and is being studied in patients undergoing endovascular thrombectomy (EVT). The drug is administered in a hospital setting for this acute neurological condition.
The specific molecular target of LT3001 Drug Product has not been disclosed in available information. It is classified as a small molecule therapeutic intended for acute ischemic stroke. The exact mechanism of action is not publicly detailed, and no target class has been specified for this investigational drug.
LT3001 Drug Product is being developed by cbdMD, Inc., a company publicly traded under the ticker symbol YCBD. The company is advancing this investigational therapy through clinical trials for acute ischemic stroke, with the drug currently in Phase 2 development.
LT3001 Drug Product is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting participants to evaluate the drug's safety and efficacy in patients with acute ischemic stroke.
LT3001 Drug Product is being studied in one active Phase 2 clinical trial with the identifier NCT05198323. This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of the drug in subjects with acute ischemic stroke undergoing endovascular thrombectomy. The trial is recruiting 66 participants in the United States and Taiwan.
LT3001 Drug Product is a distinct investigational small molecule being developed specifically for acute ischemic stroke. No alternative names have been associated with this drug in available information. It is being studied as a potential treatment option for patients undergoing endovascular thrombectomy, but it is not the same as other approved stroke therapies.